APR 0 2 2004 pm

PTO/SB/08a(08/03)
Approved for use through 07/31/2006. OMB 0651-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

sperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid. OMB control number. Application Number Substitute for form 10/642,440 Filing Date August 14, 2003 INFORMATION DISCLOSURE First Named Inventor Eli Wallace STATEMENT BY APPLICANT Art Unit (Use as many sheets as necessay) **Examiner Name** of Sheet Attorney Docket No. ARR002 NON PATENT LITERATURE DOCUMENTS Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, T<sup>2</sup> Initials\* No.1 magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published DAVID W. RUSNAK, et al., The Effects of the Novel, Reversible Epidermal Growth Factor Receptor/ErbB-2 Tyrosine Kinase Inhibitor, GW2016, on the Growth of Human Normal and Tumor-derived Cell Lines in Vitro and in Vivo, Molecular Cancer Therapeutics, 2001, Vol. 1 (December) pp. 85-94 , DAVID W. RUSNAK, et al., The Characterization of Novel, Dual ErbB-2/EGFR, Tyrosine Kinase Inhibitors: Potential Therapy for Cancer, Cancer Research, Vol. 61, pp. 7196-7203, October 1, 2001 , **EXAMINER** DATE **SIGNATURE** CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) and application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

MAR 1 2 2004 55

ATTY, DOCKET NO. **APPLICATION NO** PTO/SB/08A (10/01) (Substitute for form 1449A/PTO) **ARR002** 10/642,440 INFORMATION DISCLOSURE FIRST NAMED INVENTOR: EII WALLACE STATEMENT BY APPLICANT (Use several sheets if necessary) **ART UNIT** FILING DATE August 14, 2003 1624 Sheet <u>1</u> of \_\_\_ **U.S. PATENT DOCUMENTS** Pages, Columns, Lines, Where Relevant Name of Patentee or **Publication Date** Cite Document No. Examiner Passages or Relevant Figures Appear MM-DD-YYYY **Applicant of Cited Doc** No. - Kind Code Initials No. AYER, et al. March 26, 1996 5,502,187 **FOREIGN PATENT DOCUMENTS** Pages, Columns. **Lines Where Relevant TRANSLATION Publication Date** Name of Patentee or **Foreign Patent Doc** Cite Examiner cntry code - No. - Kind Passages or Relevant MM-DD-YYYY **Applicant of Cited Doc** Initials No. Code Figures Appear WARNER-LAMBERT July 20, 2000 -PCT/US99/98483-COMPANY WO 00-42022 OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, Cite Examiner serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published Initials No. **EXAMINER SIGNATURE DATE CONSIDERED** EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.